Astellas Pharma Inc's ticker is ALPMY and the CUSIP is 04623U102. A total of 14 filers reported holding Astellas Pharma Inc in Q1 2017. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $1,049,000 | +6.2% | 69,038 | -10.8% | 0.12% | +6.0% |
| Q4 2017 | $988,000 | +9.3% | 77,425 | +8.9% | 0.12% | +3.5% |
| Q3 2017 | $904,000 | +4.8% | 71,107 | +0.8% | 0.11% | -0.9% |
| Q2 2017 | $863,000 | +11.8% | 70,565 | +20.3% | 0.11% | +8.6% |
| Q1 2017 | $772,000 | -4.9% | 58,645 | +0.5% | 0.10% | -11.8% |
| Q4 2016 | $812,000 | -13.8% | 58,325 | -3.8% | 0.12% | +133.3% |
| Q3 2016 | $942,000 | -7.6% | 60,610 | -7.3% | 0.05% | -13.6% |
| Q2 2016 | $1,020,000 | +12.7% | 65,410 | -3.8% | 0.06% | +15.7% |
| Q1 2016 | $905,000 | -9.0% | 68,000 | -1.6% | 0.05% | -8.9% |
| Q4 2015 | $994,000 | +10.2% | 69,090 | -1.2% | 0.06% | +1.8% |
| Q3 2015 | $902,000 | -9.8% | 69,935 | -0.2% | 0.06% | +3.8% |
| Q2 2015 | $1,000,000 | -16.7% | 70,095 | -4.3% | 0.05% | -17.2% |
| Q1 2015 | $1,201,000 | +16.6% | 73,215 | 0.0% | 0.06% | +10.3% |
| Q4 2014 | $1,030,000 | +4.4% | 73,215 | +10.4% | 0.06% | +5.5% |
| Q3 2014 | $987,000 | +16.0% | 66,325 | +2.4% | 0.06% | +19.6% |
| Q2 2014 | $851,000 | – | 64,740 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RENAISSANCE GROUP LLC | 1,006,415 | $15,080,000 | 0.60% |
| Henry James International Management Inc. | 18,078 | $271,000 | 0.12% |
| QUADRANT CAPITAL GROUP LLC | 27,557 | $407,000 | 0.07% |
| SCOUT INVESTMENTS, INC. | 210,640 | $3,156,000 | 0.06% |
| Aristotle Capital Management, LLC | 442,510 | $6,631,000 | 0.04% |
| BOSTON ADVISORS LLC | 43,966 | $658,000 | 0.03% |
| PARAMETRIC PORTFOLIO ASSOCIATES LLC | 2,560,399 | $38,329,000 | 0.03% |
| GLENMEDE TRUST CO NA | 306,283 | $4,588,000 | 0.02% |
| FULTON BANK, N.A. | 14,909 | $223,000 | 0.02% |
| Front Row Advisors LLC | 1,101 | $16,000 | 0.01% |